NIH funds more awards for infectious disease early trials

By Fiona BARRY contact

- Last updated on GMT

Related tags: Clinical trial

NIH funds more awards for infectious disease early trials
The US National Institutes of Health (NIH) has awarded funding to a third organisation performing early-stage clinical trials of infectious disease drugs.

The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, upped its funding recipients from two institutions to three, signing contracts with Ohioan contract research organisation Clinical Research Management, Duke University, and DynPort Vaccine Company in Maryland.

Under the Phase I Clinical Trial Units for Therapeutics programme, the institutions can receive a share of up to $90m to help fund clinical trials during a 10-year contract with NIAID.

The money supports the safety assessment of drug candidates against infectious diseases from viruses, bacteria, pathogens and fungi, including emerging diseases and “biodefense​” pathogens designated a priority by NIAID. HIV investigations are excluded.

This safety work can include first-in-human human trials for small molecule and mAbs, corrected QT interval (QTc) trials, and drug-drug interaction studies, as well as assay development, and analysis of bioanalytical samples.

The awards programme began in 2008 and has funded Phase I trials of influenza anti-viral therapies and treatments for MRSA and multi-drug resistant tuberculosis. It recently financed early trials of an anti-viral fusion protein against flu, including H5N1 avian flu – a drug which has since begun Phase II study.

Eligibility

An NIAID programme expert told us the three contract recipients will now be eligible for funding via “task order awards​” by applying for subcontracts for specific trials.

Criteria for awarding the money are a “bone fide need to purchase something​”, public health significance, and appropriateness and feasibility of the study design, NIAID told us.

The studies to be undertaken by Clinical Research Management, Duke and DynPort are currently undecided as the programme falls under an Indefinite Delivery Indefinite Quantity (IDIQ)​ contract, meaning the government’s specific needs are unknown at the time it is signed.

Once a need is determined and concept approved, an RTOP [Request for Task Order Proposal] is drafted and shared with the three grantee organizations. Once proposals are assessed in coordination with the evaluation criteria of the RTOP, a specific award can be made,​” said NIAID.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars